RepliCel Life Sciences Inc.

Equities

REPCF

CA76027P4006

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:20:42 2024-03-15 am EDT			5-day change	1st Jan Change
0.0428 ^USD	+4.99%		-.--%	-4.89%

Apr. 18	RepliCel Life Sciences Inc. Announces Secured Loan Agreement	CI
2023	RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.01225 million in funding

February 01, 2023

RepliCel Life Sciences Inc. announced that it will receive CAD 12,250 in funding on February 2, 2023. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. Announces Secured Loan Agreement	Apr. 17	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-23	CI
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	23-08-30	CI
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	23-08-17	CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	23-08-17	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
RepliCel Life Sciences Inc. announced that it has received CAD 1.0131 million in funding	23-03-13	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding	23-02-07	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.01225 million in funding	23-02-01	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.05 million in funding	23-01-25	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding	23-01-25	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.116419 million in funding	23-01-16	CI
RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding	23-01-05	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding	23-01-02	CI
RepliCel Life Sciences Inc. announced that it expects to receive $0.558837 million in funding	22-12-29	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
RepliCel Life Sciences Inc. Announces Executive Changes	22-11-28	CI
RepliCel Life Sciences Inc. Announces Executive Changes	22-11-28	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding	22-09-05	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise	22-08-02	CI
RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype	22-07-26	CI

Chart RepliCel Life Sciences Inc.

Duration

Period

More charts

Company Profile

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Companyâs cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REPLICEL LIFE SCIENCES INC.	-4.89%	2.78M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs